MatriSys Bioscience, a San Diego, CA-based developer of novel class of live biologic therapeutics targeting major skin and dermatologic conditions, closed a $1.5m convertible note financing round.
The round was led by Tech Coast Angels (TCA). In conjunction with the funding, Jeff Friedman, MD, PhD, deal lead and head of TCA’s life sciences committee, will join the board of MatriSys.
The company will use the funds to accelerate clinical trials for atopic dermatitis and continue preclinical work for its pipeline of live biologic therapeutics for additional clinical indications.
Led by Mark S. Wilson, CEO, MatriSys leverages advances in skin microbiome research led by Professor Richard Gallo of UCSD to produce live biological therapeutics (LBTs) that rebalance the normal mix of bacterial species present on the skin, expand good microbes and selectively remove the damaging or pathogenic species.
MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients.